MLchartDataset catalogue

efgartigimod alfa

Term · Oncology and biomedicine · MLC-T-ONC-013220

A human immunoglobulin G1 (IgG1)-derived Fc fragment that targets the neonatal Fc receptor (FcRn), with potential FcRn blocking activity. Upon administration, efgartigimod alfa targets, binds to and blocks FcRn, thereby preventing FcRn from recycling IgG back into the systemic circulation. This causes a reduction in IgG blood levels, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. FcRn binds to IgGs and prevents their lysosomal degradation, thereby extending IgG half-life and increases the availability of pathogenic IgG antibodies that are present in certain severe autoimmune diseases.

Table 1. Record
IdentifierMLC-T-ONC-013220
FieldOncology and biomedicine
Synonymsefgartigimod alfa-fcab
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-013220",
  "term": "efgartigimod alfa",
  "field": "Oncology and biomedicine",
  "definition": "A human immunoglobulin G1 (IgG1)-derived Fc fragment that targets the neonatal Fc receptor (FcRn), with potential FcRn blocking activity. Upon administration, efgartigimod alfa targets, binds to and blocks FcRn, thereby preventing FcRn from recycling IgG back into the systemic circulation. This causes a reduction in IgG blood levels, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. FcRn binds to IgGs and prevents their lysosomal degradation, thereby extending IgG half-life and increases the availability of pathogenic IgG antibodies that are present in certain severe autoimmune diseases.",
  "synonyms": [
    "efgartigimod alfa-fcab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/efgartigimod-alfa/"
}

Record 6,401 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.